31.16
price down icon0.13%   -0.04
after-market Dopo l'orario di chiusura: 31.16
loading

Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie

pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360

Jun 16, 2025
pulisher
Jun 16, 2025

Deals of the day-Mergers and acquisitions - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus makes depression drug play with $795m Sage buyout - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to buy Sage for up to $795 million - Axios

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics (SAGE) for $8.50 Per Share - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus stock in focus as Sage agrees to buy (SAGE:NASDAQ) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio | SUPN Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for up to $795 million - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Cut by Rhumbline Advisers - Defense World

Jun 13, 2025
pulisher
Jun 08, 2025

California State Teachers Retirement System Lowers Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Two Sigma Advisers LP Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LP - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Supernus at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

(SUPN) Trading Report - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 04, 2025

Supernus at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com

Jun 04, 2025
pulisher
Jun 01, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Nuveen Asset Management LLC - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Supernus (SUPN) Partners with Jay Glazer for ADHD Awareness Series | SUPN Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and R - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals | SUPN Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree - Nasdaq

May 29, 2025
$14.29
price down icon 0.07%
$9.01
price down icon 1.21%
$125.42
price down icon 1.02%
$284.27
price up icon 0.06%
drug_manufacturers_specialty_generic RDY
$15.07
price down icon 1.70%
$16.76
price up icon 1.21%
Capitalizzazione:     |  Volume (24 ore):